As of 2024-12-12, the EV/EBITDA ratio of Regenxbio Inc (RGNX) is -1.78. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. RGNX's latest enterprise value is 404.20 mil USD. RGNX's TTM EBITDA according to its financial statements is -227.27 mil USD. Dividing these 2 quantities gives us the above RGNX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 14.7x - 17.4x | 16.0x |
| Forward P/E multiples | 15.7x - 21.4x | 15.8x |
| Fair Price | (71.05) - (78.57) | (71.78) |
| Upside | -864.0% - -944.9% | -871.9% |
| Date | EV/EBITDA |
| 2024-11-22 | -1.84 |
| 2024-11-21 | -1.75 |
| 2024-11-20 | -1.85 |
| 2024-11-19 | -1.84 |
| 2024-11-18 | -1.96 |
| 2024-11-15 | -1.85 |
| 2024-11-14 | -2.18 |
| 2024-11-13 | -2.08 |
| 2024-11-12 | -2.04 |
| 2024-11-11 | -2.27 |
| 2024-11-08 | -2.18 |
| 2024-11-07 | -2.19 |
| 2024-11-06 | -1.81 |
| 2024-11-05 | -1.70 |
| 2024-11-04 | -1.66 |
| 2024-11-01 | -1.67 |
| 2024-10-31 | -1.62 |
| 2024-10-30 | -1.68 |
| 2024-10-29 | -1.73 |
| 2024-10-28 | -1.80 |
| 2024-10-25 | -1.79 |
| 2024-10-24 | -1.84 |
| 2024-10-23 | -1.87 |
| 2024-10-22 | -1.84 |
| 2024-10-21 | -2.01 |
| 2024-10-18 | -2.17 |
| 2024-10-17 | -2.06 |
| 2024-10-16 | -2.09 |
| 2024-10-15 | -2.00 |
| 2024-10-14 | -1.97 |
| 2024-10-11 | -1.91 |
| 2024-10-10 | -1.78 |
| 2024-10-09 | -1.77 |
| 2024-10-08 | -1.84 |
| 2024-10-07 | -1.83 |
| 2024-10-04 | -1.87 |
| 2024-10-03 | -1.79 |
| 2024-10-02 | -1.91 |
| 2024-10-01 | -1.98 |
| 2024-09-30 | -2.04 |
| 2024-09-27 | -2.11 |
| 2024-09-26 | -2.08 |
| 2024-09-25 | -2.11 |
| 2024-09-24 | -2.19 |
| 2024-09-23 | -2.30 |
| 2024-09-20 | -2.30 |
| 2024-09-19 | -2.48 |
| 2024-09-18 | -2.48 |
| 2024-09-17 | -2.57 |
| 2024-09-16 | -2.53 |